drugset / Trial / NCT02056392

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

NCT02056392

Phase 1 Completed 54 enrolled AstraZeneca
RandomizedCrossoverQuadruple-blindBasic science

Summary

Study to assess the effect of Selumetinib \[AZD6244; ARRY-142886\] \[Hyd-Sulfate\]), on QTc interval in healthy male volunteers.

Timeline

Start
2014-03
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Selumetinib Small molecule 75 mg Oral

Indications